ADIA Nutrition Inc. Announces Registration with RangeMe and Submission for Walmart’s Open Call

health news

Winter Park, Florida–(Newsfile Corp. – August 6, 2024) – ADIA Nutrition Inc. (OTC Pink: ADIA), an innovative provider of nutritional supplements, is pleased to announce its recent registration with RangeMe, a leading product discovery platform, and the submission of an application for Walmart’s Open Call event in September.

The registration with RangeMe allows ADIA Nutrition to showcase its unique product, Biolete, to over 15,000 buyers from various retailers, including Walmart, CVS, and 7-11 to name a few. Biolete is a pioneering protein coffee with mushrooms, designed to provide a delicious and nutritious beverage option for health-conscious consumers.

Cannot view this image? Visit: https://healthtechnologynet.com/wp-content/uploads/2024/08/218842_adia1.jpg

Biolete

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/218842_adia1en.jpg

“We are excited to join the RangeMe platform and showcase Biolete to a wide range of buyers,” said Larry Powalisz, CEO of ADIA Nutrition Inc. “This registration represents a significant step forward in our efforts to expand our distribution channels and bring Biolete to more consumers across the country.”

In addition to the RangeMe registration, ADIA Nutrition has also submitted an application for Walmart’s Open Call event, scheduled for September. The event provides an opportunity for suppliers to pitch their products directly to Walmart’s buyers and potentially secure a spot on Walmart’s shelves.

“We are thrilled to submit our application for Walmart’s Open Call event,” added Powalisz. “We believe Biolete’s unique combination of protein and adaptogens will resonate with Walmart’s customers, and we look forward to the opportunity to present our product to their buyers.”

ADIA Nutrition’s strategic move to register with RangeMe and submit an application for Walmart’s Open Call event aligns with the company’s mission to revolutionize the supplement industry and empower individuals to prioritize their health and well-being.

For media inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.

About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division specializing in Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments for Multiple Sclerosis (MS). Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.

Website: www.adianutrition.com

Website: www.adia-med.com

Website: www.biolete.com

Website: www.cementfactory.com

Twitter (X): @ADIA_Nutrition

Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company’s current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/218842